Jordi Abril-Fornaguera

7PUBLICATIONS
63CO-AUTHORS
Haematological tumoursMolecular targetsCancer therapy (excl. chemotherapy and radiation therapy)Applied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)Medical biochemistry - proteins and peptides (incl. medical proteomics)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (7)

|Dec 08, 2025
Effective therapeutic targeting of CTNNB1-mutant hepatoblastoma with WNTinib.

Ugne Balaseviciute, Júlia Huguet-Pradell, Jordi Abril-Fornaguera

|Sep 23, 2025
E7386 Enhances Lenvatinib's Antitumor Activity in Preclinical Models and Human Hepatocellular Carcinoma.

Agavni Mesropian, Albert Gris-Oliver, Ugne Balaseviciute

|Aug 03, 2023
WNTinib is a multi-kinase inhibitor with specificity against β-catenin mutant hepatocellular carcinoma.

Alex Rialdi, Mary Duffy, Alex P Scopton

|Feb 13, 2023
Identification of IGF2 as Genomic Driver and Actionable Therapeutic Target in Hepatoblastoma.

Jordi Abril-Fornaguera, Laura Torrens, Carmen Andreu-Oller

|Mar 18, 2022
Cabozantinib Enhances Anti-PD1 Activity and Elicits a Neutrophil-Based Immune Response in Hepatocellular Carcinoma.

Roger Esteban-Fabró, Catherine E Willoughby, Marta Piqué-Gili

|Jun 22, 2021
Immunomodulatory Effects of Lenvatinib Plus Anti-Programmed Cell Death Protein 1 in Mice and Rationale for Patient Enrichment in Hepatocellular Carcinoma.

Laura Torrens, Carla Montironi, Marc Puigvehí

Pageof 2

Frequent Collaborators

6 joint publications

Josep M Llovet

4 joint publications

Carla Montironi

4 joint publications

Ernesto Guccione

4 joint publications

Agavni Mesropian